## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($92.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Should You Hold On To BSX Stock Despite Its Premium Valuation?**
- Source: Finviz | 20251223T140727 | Somewhat-Bullish | Relevance: 100%
- Boston Scientific (BSX) is currently trading at a premium valuation compared to its industry and rivals, with a forward five-year P/E of 27.77X. Despite this, the company demonstrates steady growth in its MedSurg businesses, particularly in Urology and Endoscopy, and continues to see strong momentum in its WATCHMAN and Electrophysiology segments. Analysts remain bullish, suggesting that existing investors might hold their positions, while new investors should await a better entry point.

**2. Boston Scientific Corporation $BSX is Munro Partners' 8th Largest Position**
- Source: MarketBeat | 20251224T125721 | Bullish | Relevance: 100%
- Munro Partners significantly increased its stake in Boston Scientific Corporation (NYSE: BSX) during Q3, making it the firm's 8th largest holding. The medical equipment provider exceeded Q3 estimates and has received a consensus "Buy" rating from analysts with a price target of $124.85. Hedge funds and other institutional investors own a substantial 89.07% of the company's stock, though some insiders recently sold shares.

**3. Boston Scientific head of cardiac rhythm management, diagnostics to retire, successor named**
- Source: MassDevice | 20251223T152923 | Neutral | Relevance: 100%
- Scott Olson, SVP and president of Boston Scientificâ€™s Cardiac Rhythm Management & Diagnostics (CRMDx) business, announced his retirement at the end of 2025. Angelo De Rosa, who previously led the Watchman business, will succeed Olson as president of CRMDx and join the Boston Scientific executive committee at the start of 2026. De Rosa will focus on advancing cardiac care with a mission to innovate and deliver for clinicians and patients.

**4. Westwind Capital Takes $13.80 Million Position in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20251223T142027 | Bullish | Relevance: 100%
- Westwind Capital has acquired a new position in Boston Scientific Corporation, purchasing 141,343 shares valued at approximately $13.80 million, making it their 16th largest holding. Boston Scientific exceeded Q3 expectations with strong earnings and revenue, and the stock is heavily owned by institutional investors. Insiders have recently sold off a significant number of shares.

**5. Is Boston Scientific Corp. (BSX) Positioned for Solid, Durable Growth?**
- Source: Insider Monkey | 20251223T080500 | Somewhat-Bullish | Relevance: 100%
- Parnassus Investments initiated a position in Boston Scientific Corporation (NYSE:BSX) in the third quarter of 2025, viewing it as an innovative medical device maker with significant growth drivers. The company's first-mover advantage, robust clinical data, and strong physician relationships enable it to maintain dominant market share and outgrow competitors. Management's disciplined R&D and M&A strategies are driving organic sales growth and margin expansion, positioning Boston Scientific for durable growth amidst expanding margins and global demand tailwinds.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 9 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.5B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 27.7 |
| Current P/E | 31.7 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.9% to 0.2% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 (-1.0%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 48. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.17% (CS: 76) | Neutral |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | 0.37 | Bullish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 0.951x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.04
- **Stop Loss:** $92.08 (4.1% risk)
- **Target:** $100.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 303
- **Position Value:** $29,100.12
- **Portfolio %:** 29.10%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*